Business
Grant of Options under Long Term Incentive Scheme
Allergy Therapeutics plc announced on January 28, 2026, that it granted share option awards to key management personnel, including persons discharging managerial responsibilities, on January 27, 2026. These options are designed to incentivize long-term value creation and align management interests with stakeholders, with 70% vesting based on Adjusted EBITDA performance and 30% on share price performance over a three-year period. The Chief Executive Officer received 5,409,724 options, and the Chief Financial Officer received 2,489,627 options, both with an exercise price of £0.001. Following these grants, the company has options outstanding over 365,205,852 ordinary shares, representing 5.95% of its current issued share capital. Disclaimer*
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n\n\nAllergy Therapeutics plc\n(\"Allergy Therapeutics\" or the \"Company\" or the \"Group\")\n \nGrant of Options under Long Term Incentive Scheme\n \n28 January 2026: Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapies, today announces that on 27 January 2026 it granted share option awards to key members of Allergy Therapeutics' management team including certain of its persons discharging managerial responsibilities (\"PDMRS\").\n \nThe Board has granted options to encourage long-term value creation for the Company's shareholders, and so that the individuals identified as key people to lead the business into the future are appropriately incentivised in a manner that aligns with the interests of the Group's stakeholders.\n \nVesting is conditional on the satisfaction of performance criteria over a three-year period. Vesting of 70 per cent. of the award subject to Adjusted EBITDA* performance and vesting of the remaining 30 per cent. of the award is subject to share price performance.\n \nThe following awards have been made in accordance with the Group LTIP:\n \n\n\n\n\nName\n\n\nTitle\n\n\nNumber of share options granted\n\n\nResultant \nnumber of share options held\n\n\nPerformance period\n\n\nVesting Date\n\n\nExercise price\n\n\nNumber of \nOrdinary Shares\nheld\n\n\n\n\nManuel Llobet\n\n\nChief Executive Officer\n\n\n5,409,724\n\n\n142,578,024\n\n\n3 years commencing 1 July 2025\n\n\n30 June 2028\n\n\n£0.001\n\n\n5,001,200\n\n\n\n\nShaun Furlong\n\n\nChief Financial Officer\n\n\n2,489,627\n\n\n21,704,724\n\n\n3 years commencing 1 July 2025\n\n\n30 June 2028\n\n\n£0.001\n\n\n1,507\n\n\n\n\n \nThe number of Ordinary Shares stated above is the maximum number that could be issued to each PDMR upon full satisfaction of the performance conditions attached to the awards.\n \nThe Group's Remuneration Committee will review the performance conditions at periodic intervals to ensure they remain appropriate. As a result of any such review, the Committee will retain discretion to amend the conditions where appropriate having regard to overall Company performance and wider stakeholder experience.\n \nFollowing the above grants of options, the Company has options outstanding over 365,205,852 ordinary ...